trial · primary record
Alectinib
Non-Small Cell Lung Cancer
| Phase | Phase 3 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 68 |
| Primary completion | 2030-06-16 |
| Primary endpoint | Progression-free Survival (PFS), as Determined by Blinded Independent Central Review (BICR) per Response Evaluation Criterial in Solid Tumors Version 1.1 (RECIST V1.1) |
| Registry ID | NCT05170204 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:44:11.462Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05170204
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.